Call  +41 61 926 6040
Fax +41 61 926 6049
Toggle Nav
My Cart
Search
Advanced Search
Account
Settings
Toggle Nav

AdipoGen Life Sciences

Fostriecin

CHF 240.00
In stock
AG-CN2-0057-C01010 µgCHF 240.00
Call  +41 61 926 6040
Fax  +41 61 926 6049
Contact Us!
Loading...
More Information
Product Details
Synonyms Phosphotrienin; CI-920; CL-1565A; NSC-339638; PD 110,161; Pyranone phosphate
Product Type Chemical
Properties
Formula

C19H26O9PNa
MW 452.4
CAS 87860-39-7
RTECS UQ0600000
Source/Host Chemicals Isolated from Streptomyces pulveraceous.
Purity Chemicals ≥95% (HPLC)
Appearance Colorless solid.
Solubility Soluble in water, methanol or ethanol.
Other Product Data

Use only fresh solutions.
InChi Key XBUIKNRVGYFSHL-CZYWAGOEBB
Smiles [Na+].C[C@@](O)(\C=C\[C@H]1CC=CC(=O)O1)[C@@H](C[C@@H](O)\C=C/C=C\C=C\CO)OP(O)([O-])=O
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Hygroscopic.
Keep cool and dry.
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
Documents
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
Description
  • Antibiotic [1, 2, 18].
  • Anticancer compound [1-5, 8, 9, 11].
  • Antifungal [6].
  • Catalytic inhibitor of topoisomerase II (IC50 = 40 μM) [7, 16].
  • Potent protein phosphatase 2A (PP2A) (IC50 = 1.5 nM) and 4 (PP4) (IC50 = 3 nM) inhibitor [10, 12, 15].
  • Weak protein phosphatase type 1 (PP1) inhibitor (IC50=131µM). No apparent inhibition on PP2B [10, 12].
  • Mitotic entry checkpoint inhibitor [10]. Mediates cell cycle arrest at G2-M-phase [14].
  • Ischemia protective [13].
  • The PP2A binding site is different from that of okadaic acid [17, 19]
Product References
  1. Novel antitumor agents CI-920, PD 113,270 and PD 113,271. I. Taxonomy, fermentation and biological properties: J.B. Tunac, et al.; J. Antibiot. (Tokyo) 36, 1595 (1983)
  2. Novel antitumor agents CI-920, PD 113,270 and PD 113,271. II. Isolation and characterization: S.S. Stampwala, et al.; J. Antibiot. (Tokyo) 36, 1601 (1983)
  3. Studies on the biochemical mechanism of the novel antitumor agent, CI- 920: D.W. Fry, et al.; Cancer Chemother. Pharmacol. 13, 171 (1984)
  4. Anticancer activity of the structurally novel antibiotic Cl-920 and its analogues: W.R. Leopold, et al.; Cancer Res. 44, 1928 (1984)
  5. In vitro activity of the novel antitumor antibiotic fostriecin (CI-920) in a human tumor cloning assay: W. Scheithauer, et al.; Eur. J. Cancer Clin. Oncol. 22, 921 (1986)
  6. Antimycotic effects of the novel antitumor agents fostriecin (CI-920), PD 113,270 and PD 113,271: S.W. Mamber, et al.; J. Antibiot. (Tokyo) 39, 1467 (1986)
  7. Inhibition of type II topoisomerase by fostriecin: T.J. Boritzki, et al.; Biochem. Pharmacol. 37, 4063 (1988)
  8. Cytostatic and cytotoxic effects of fostriecin on human promyelocytic HL-60 and lymphocytic MOLT-4 leukemic cells: M.A. Hotz, et al.; Cancer Res. 52, 1530 (1992)
  9. Changes in nuclear chromatin related to apoptosis or necrosis induced by the DNA topoisomerase II inhibitor fostriecin in MOLT-4 and HL-60 cells are revealed by altered DNA sensitivity to denaturation: M.A. Hotz, et al.; Exp. Cell Res. 201, 184 (1992)
  10. Antitumor drug fostriecin inhibits the mitotic entry checkpoint and protein phosphatases 1 and 2A: M. Roberge, et al.; Cancer Res. 54, 6115 (1994)
  11. Fostriecin: a review of the preclinical data: R.S. de Jong, et al.; Anticancer Drugs 8, 413 (1997)
  12. Fostriecin, an antitumor antibiotic with inhibitory activity against serine/threonine protein phosphatases types 1 (PP1) and 2A (PP2A), is highly selective for PP2A: A.H. Walsh, et al.; FEBS Lett. 416, 230 (1997)
  13. Fostriecin, an inhibitor of protein phosphatase 2A, limits myocardial infarct size even when administered after onset of ischemia: C. Weinbrenner, et al.; Circulation 98, 899 (1998)
  14. Fostriecin-mediated G2-M-phase growth arrest correlates with abnormal centrosome replication, the formation of aberrant mitotic spindles, and the inhibition of serine/threonine protein phosphatase activity: A. Cheng, et al.; Cancer Res. 58, 3611 (1998)
  15. Purification of protein phosphatase 4 catalytic subunit: inhibition by the antitumour drug fostriecin and other tumour suppressors and promoters:  C.J. Hastie & P.T. Cohen; FEBS Lett. 431, 357 (1998)
  16. Phase I and pharmacokinetic study of the topoisomerase II catalytic inhibitor fostriecin: R.S. de Jong, et al.; Br. J. Cancer 79, 882 (1999)
  17. The predicted beta12-beta13 loop is important for inhibition of PP2Acalpha by the antitumor drug fostriecin: D.R. Evans & J.A. Simon; FEBS Lett. 498, 110 (2001)
  18. Fostriecin: chemistry and biology: D.S. Lewy, et al.; Curr. Med. Chem. 9, 2005 (2002)
  19. Antitumor antibiotic fostriecin covalently binds to cysteine-269 residue of protein phosphatase 2A catalytic subunit in mammalian cells: T. Takeuchi, et al.; Bioorg. Med. Chem. 17, 8113 (2009)
Related Products
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.